LucieFournier

Associate

Brussels + 32.2.645.15.47

Lucie Fournier works on European data protection and cybersecurity law, with a focus on implementing EU General Data Protection Regulation (GDPR) and ePrivacy Regulation compliance. She advises multinational clients in various industry sectors such as information and communications technology, cloud computing, IT, life sciences, automotive, financial services, and agribusiness.

Lucie's practice includes handling personal data breaches, responding to data subject access requests, and advising clients on international transfers of personal data (e.g., drafting binding corporate rules), data protection impact assessments, employee monitoring tools, and whistleblowing schemes.

Lucie also advises clients on data protection issues in investigations and cross-border M&A transactions and assists clients on data processing agreements.

Prior to joining Jones Day, Lucie completed legal traineeships in the intellectual property and IT department of a U.S. law firm in Paris and at the French Ministry of Defense in Paris. She also has in-house experience as a legal adviser at a UK multinational company that focuses on defense, aerospace, and cybersecurity.

Experience

  • STERIS to acquire Cantel Medical for $3.6 billionJones Day is advising STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day is advising Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • International chemicals producer conducts internal auditJones Day is advising an international chemicals producer in conducting a multi-national internal antitrust audit.
  • Bombardier to sell transportation business to Alstom for €6.2 billionJones Day is serving as antitrust and French corporate counsel in the €6.2 billion sale of Bombardier Inc.'s transportation business to Alstom S.A.
  • Milliken & Company acquires Borchers from The Jordan CompanyJones Day advised Milliken & Company in its acquisition of Borchers Group Limited, a global specialty chemicals company known for its innovative high-performance coating additives and specialty catalyst solutions, from The Jordan Company, L.P.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.